Weight-management treatment is more than choosing an injection or reaching a number by a deadline. The useful questions concern health, function, treatment burden, adverse effects and whether a plan can be sustained. An online comparison can introduce options, but it cannot determine which medicine is appropriate for you or predict your individual result.
This guide is written for Canadian adults preparing or reviewing care. It does not provide a dose-escalation schedule, recommend a switch or promise a prescription through Care365. Use your exact Canadian product information and an individual clinical plan.
Start with health goals and assessment
Discuss the health concerns you want to address, previous treatment, eating patterns, activity, sleep, medicines and practical barriers. Weight and BMI are pieces of information, not a complete account of health. Ask what outcomes will be followed besides weight, such as functioning or a relevant health measure.
Avoid setting a target from another person's three-month result. Individual response and circumstances vary. A plan should be realistic about monitoring, cost, availability and follow-up. Tell the professional about pregnancy plans, breastfeeding or other health circumstances before treatment decisions are made.
Know the ingredient and the indication
Semaglutide, tirzepatide and liraglutide are different ingredients. Names such as Wegovy, Ozempic, Zepbound, Mounjaro and Saxenda refer to particular products, with product-specific indications, devices and directions. Do not assume that products sharing an ingredient or appearing in the same advertisement are interchangeable.
Ask which exact product is being considered and why. A diabetes indication and a weight-management indication are not the same thing. Use the Canadian monograph, not a US advertisement, when discussing approved use. A medicine appearing in Care365's educational library does not guarantee it is appropriate or available through a particular service.
Comparing semaglutide, tirzepatide and liraglutide
A useful comparison looks at the evidence relevant to your health situation, expected benefit, adverse effects, route, follow-up and cost. The 2025 Canadian obesity pharmacotherapy guidance describes individualised treatment rather than a single option for everyone.
Ask the clinician to explain the decision in terms of your priorities. If you are concerned about injections, treatment burden or supply, say so. Do not choose from a headline about the “best injection” without understanding the product and plan. Different study results cannot be treated as a personal forecast.
Dose changes and switching need instructions
Follow your prescribed schedule and the instructions for your device. Do not accelerate dose changes to chase appetite suppression or faster weight loss. If a dose is missed or treatment is interrupted, ask for product-specific advice; the right response may depend on the length of the gap and other circumstances.
Switching from semaglutide to tirzepatide, or between products such as Wegovy and Zepbound, is not a do-it-yourself conversion. Ask who will coordinate the change, what to stop, what to start and how follow-up will work. Do not overlap medicines because you have remaining supply unless explicitly instructed by your prescriber.
Progress is not only appetite suppression
Tell the professional what has changed in hunger, eating, functioning and relevant health measures. A medicine not producing a particular sensation does not automatically mean that the dose should increase. If progress differs from expectations, review the whole plan rather than assuming a personal failure.
Bring barriers such as cost, missed treatment, side effects, sleep or difficulty following the plan. “Not losing weight on semaglutide” is a starting question, not a diagnosis of why the plan is not working. A review can clarify what needs adjustment and whether the treatment remains appropriate.
Nausea, fatigue and other unwanted changes
Ask which common and serious adverse effects apply to your product and what action to take. Report persistent nausea, vomiting, inability to maintain fluids, significant abdominal symptoms or other concerning changes promptly. Severe symptoms need urgent assessment rather than waiting for a routine follow-up.
If you notice fatigue, hair shedding or changes in facial appearance, describe the timing, degree and other symptoms. Do not assume that every change has one cause or that an internet label such as “Ozempic face” is a diagnosis. Nutritional intake, other conditions and the overall treatment course may need review.
Other weight-management medicines
Canadian discussions may also include naltrexone/bupropion and orlistat. These are not interchangeable with incretin-based injections and have their own precautions. Ask about the exact product, indication, interactions and what monitoring is needed.
Foreign content may mention phentermine, Qsymia, Foundayo or other products. Do not infer Canadian authorisation, current marketing status or availability from a US article. Check the Canadian record and professional advice. A separate ingredient being available does not establish that a foreign combination product is available or suitable.
Stopping and long-term planning
Before starting, ask how long treatment may be needed and what happens if it is stopped. Canadian guidance treats medication as part of an ongoing management strategy; weight regain can occur after discontinuation. That possibility should be discussed without blaming the person or assuming that treatment must continue unchanged forever.
If you want to stop because of cost, adverse effects, pregnancy planning or another reason, contact the professional managing treatment. Ask what follow-up and alternative support are appropriate. Avoid rationing or changing the schedule silently, since the clinician then cannot assess the plan you are actually following.
Access, shortages and a legitimate supply
Ask about the assessment, prescription, dispensing and medication costs separately. Insurance coverage and Canadian authorisation are different questions. If supply is interrupted, contact the pharmacist and prescriber rather than buying from an unverified seller or using another person's device.
Care365's obesity resources and relevant medication guides can help you prepare questions for a weight-management assessment. Review the current service details and eligibility. An intake does not guarantee a medicine, and a blog does not establish that a particular product is in stock.
Common questions
How much weight should I lose in three months?
An individual result cannot be predicted from a headline. Agree on realistic health goals and review measures with your clinician.
Can I switch injections using an online conversion chart?
No. Ask the prescriber for a product-specific transition and follow-up plan.
Does a US approval mean a medicine is available in Canada?
No. Check Canadian authorisation, current product status and actual pharmacy supply separately.
Sources
Related medication guides
Read the guide for the exact product discussed with your healthcare professional.
Written by Care365 Editorial. Sources checked September 8, 2026. General educational information; individual care depends on an appropriate assessment.
Turn information into a conversation about your care.
You do not need to have every answer before asking for help. Start by describing your health goals, treatment history and questions about follow-up. Care365 brings patient resources, online intake and information about our healthcare professionals together in one place.
Explore weight-management care →Looking for a virtual doctor in Ontario?
Meet the doctors and healthcare professionals listed on Care365, explore their profiles and check the care options available for your concern. Our patient guides cover Canadian topics; current Care365 services are focused on Ontario.
Meet our providers →Make an online consultation count
Bring examples of what has changed, your medication list and the questions that matter most to you. An online doctor can decide whether a concern is suitable for virtual care or needs an in-person examination, testing or another service.
Find your starting point →Have questions about online prescriptions?
A prescription is a clinical decision after an appropriate assessment. Ask about treatment options, benefits, risks and follow-up. Starting an intake does not guarantee a prescription, a particular medicine or a renewal; availability depends on the service and your circumstances.
Explore medication guides →Before starting, check service eligibility, availability and any fees. Read Ontario’s guidance on virtual care.
